Abstract
Exogenous surfactant is critical in the treatment of neonates with respiratory distress syndrome. Lucinactant (Surfaxin; Discovery Laboratories, Inc.) is a surfactant replacement therapy containing sinulpeptide, which may reduce lung inflammation. This study tested whether Lucinactant reduces markers of inflammation, damage and remodeling in human airway epithelial cells exposed to hyperoxia. Calu-3 monolayers cultured at an air–liquid interface were treated apically with 140 μL of normal saline, Lucinactant or Beractant (Survanta; Abbott Laboratories, Inc.). Treated monolayers were exposed to 60% O2/5% CO2 for 24 or 72 h. Transepithelial resistance (TER; p < 0.001) and cell viability (p < 0.05) were greater in both surfactant groups compared with saline; by 72 h Lucinactant cells had greater TER than Beractant (p < 0.001). Surfactant treated groups secreted less IL-8 than saline (p < 0.001), whereas Lucinactant cells secreted less IL-6 than saline and Beractant (p < 0.001). Matrix metalloproteinase 7, expressed by saline and Beractant treated cells at 24 h, was attenuated by 72 h by Beractant (p < 0.001), but was never detected in Lucinactant cells. Histology indicated less injury with Lucinactant relative to Beractant and saline. These data suggest that Lucinactant was protective compared with Beractant and control.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- ASF:
-
apical surface wash fluid
- BPD:
-
bronchopulmonary dysplasia
- KL4 (sinulpeptide):
-
synthetic peptide that mimics
- MMP:
-
matrix metalloproteinase SP-B
- SP-B:
-
surfactant protein B
- TER:
-
transepithelial resistance
References
Jobe AH, Ikegami M, Jacobs HC, Jones SJ 1983 Surfactant pool sizes and severity of respiratory distress syndrome in prematurely delivered lambs. Am Rev Respir Dis 127: 751–755
Falciglia HS, Johnson JR, Sullivan J, Hall CF, Miller JD, Riechmann GC, Falciglia GA 2003 Role of antioxidant nutrients and lipid peroxidation in premature infants with respiratory distress syndrome and bronchopulmonary dysplasia. Am J Perinatol 20: 97–107
Mentro AM 2004 Vitamin A and bronchopulmonary dysplasia: research, issues, and clinical practice. Neonatal Netw J Neonatal Nurs 23: 19–23
Loughran-Fowlds A, Oei J, Wang H, Xu H, Wimalasundera N, Egan C, Henry R, Lui K 2006 The influence of gestation and mechanical ventilation on serum clara cell secretory protein (CC10) concentrations in ventilated and nonventilated newborn infants. Pediatr Res 60: 103–108
Splawski JB, Yamamoto K, Lipsky PE 1998 Deficient interleukin-10 production by neonatal T cells does not explain their ineffectiveness at promoting neonatal B cell differentiation. Eur J Immunol 28: 4248–4256
Chess PR, D'Angio CT, Pryhuber GS, Maniscalco WM 2006 Pathogenesis of bronchopulmonary dysplasia. Semin Perinatol 30: 171–178
Bhandari A, Bhandari V 2003 Pathogenesis, pathology and pathophysiology of pulmonary sequelae of bronchopulmonary dysplasia in premature infants. Front Biosci 8: e370–e380
Clement A 1996 Bronchopulmonary dysplasia. Rev Mal Respir 13: 243–249
Hilgendorff A, Rawer D, Doerner M, Tutdibi E, Ebsen M, Schmidt R, Guenther A, Gortner L, Reiss I 2003 Synthetic and natural surfactant differentially modulate inflammation after meconium aspiration. Intensive Care Med 29: 2247–2254
Meyer KC, Zimmerman JJ 2002 Inflammation and surfactant. Paediatr Respir Rev 3: 308–314
De Dooy JJ, Mahieu LM, Van Bever HP 2001 The role of inflammation in the development of chronic lung disease in neonates. Eur J Pediatr 160: 457–463
Bakowska J, Adamson IY 1998 Collagenase and gelatinase activities in bronchoalveolar lavage fluids during bleomycin-induced lung injury. J Pathol 185: 319–323
Danan C, Jarreau PH, Franco ML, Dassieu G, Grillon C, Abd Alsamad I, Lafuma C, Harf A, Delacourt C 2002 Gelatinase activities in the airways of premature infants and development of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 283: L1086–L1093
Corbel M, Belleguic C, Boichot E, Lagente V 2002 Involvement of gelatinases (MMP-2 and MMP-9) in the development of airway inflammation and pulmonary fibrosis. Cell Biol Toxicol 18: 51–61
Nogee LM, Wert SE, Proffit SA, Hull WM, Whitsett JA 2000 Allelic heterogeneity in hereditary surfactant protein B (SP-B) deficiency. Am J Respir Crit Care Med 161: 973–981
Frerking I, Gunther A, Seeger W, Pison U 2001 Pulmonary surfactant: functions, abnormalities and therapeutic options. Intensive Care Med 27: 1699–1717
Revak SD, Merritt TA, Cochrane CG, Heldt GP, Alberts MS, Anderson DW, Kheiter A 1996 Efficacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. Pediatr Res 39: 715–724
Wiswell TE, Smith RM, Katz LB, Mastroianni L, Wong DY, Willms D, Heard S, Wilson M, Hite RD, Anzueto A, Revak SD, Cochrane CG 1999 Bronchopulmonary segmental lavage with Surfaxin (KL(4)-surfactant) for acute respiratory distress syndrome. Am J Respir Crit Care Med 160: 1188–1195
Babu PB, Chidekel A, Shaffer TH 2005 Hyperoxia-induced changes in human airway epithelial cells: the protective effect of perflubron. Pediatr Crit Care Med 6: 188–194
Zhu Y, Miller TL, Singhaus CJ, Shaffer TH, Chidekel A 2008 Effects of oxygen concentration and exposure time on cultured human airway epithelial cells. Pediatr Crit Care Med 9: 224–229
Babu PB, Chidekel A, Shaffer TH 2004 Protein composition of apical surface fluid from the human airway cell line Calu-3: effect of ion transport mediators. Clin Chim Acta 347: 81–88
Zhang Y, Reenstra WW, Chidekel A 2001 Antibacterial activity of apical surface fluid from the human airway cell line Calu-3: pharmacologic alteration by corticosteroids and beta(2)-agonists. Am J Respir Cell Mol Biol 25: 196–202
Coyne CB, Vanhook MK, Gambling TM, Carson JL, Boucher RC, Johnson LG 2002 Regulation of airway tight junctions by proinflammatory cytokines. Mol Biol Cell 13: 3218–3234
Miller TL, Touch SM, Singhaus CJ, Ramesh Babu PB, Chidekel A, Shaffer TH 2006 Expression of matrix metalloproteinases 2, 7 and 9, and their tissue inhibitors 1 and 2, in developing rabbit tracheae. Biol Neonate 89: 236–243
Foster KA, Avery ML, Yazdanian M, Audus KL 2000 Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery. Int J Pharm 208: 1–11
Borchard G, Cassara ML, Roemele PE, Florea BI, Junginger HE 2002 Transport and local metabolism of budesonide and fluticasone propionate in a human bronchial epithelial cell line (Calu-3). J Pharm Sci 91: 1561–1567
Cowley EA, Linsdell P 2002 Oxidant stress stimulates anion secretion from the human airway epithelial cell line Calu-3: implications for cystic fibrosis lung disease. J Physiol 543: 201–209
Bals R, Weiner DJ, Wilson JM 1999 The innate immune system in cystic fibrosis lung disease. J Clin Invest 103: 303–307
Smith JJ, Travis SM, Greenberg EP, Welsh MJ 1996 Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 85: 229–236
Travis SM, Conway BA, Zabner J, Smith JJ, Anderson NN, Singh PK, Greenberg EP, Welsh MJ 1999 Activity of abundant antimicrobials of the human airway. Am J Respir Cell Mol Biol 20: 872–879
Kinniry P, Pick J, Stephens S, Jain D, Solomides CC, Niven R, Segal R, Christofidou-Solomidou M 2006 KL4-surfactant prevents hyperoxic and LPS-induced lung injury in mice. Pediatr Pulmonol 41: 916–928
Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A, Kornacka MK, Merritt TA, Segal R, Schaber CJ, Tsai H, Massaro J, d'Agostino R 2005 A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics 115: 1018–1029
Moya F, Sinha S, Gadzinowski J, D'Agostino R, Segal R, Guardia C, Mazela J, Liu G 2007 One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics 119: e1361–e1370
Soll RF, Blanco F 2001 Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2: CD000144
Krause MF, Wiemann T, Reisner A, Orlowska-Volk M, Kohler H, Ankermann T 2005 Surfactant reduces extravascular lung water and invasion of polymorphonuclear leukocytes into the lung in a piglet model of airway lavage. Pulm Pharmacol Ther 18: 129–139
Bhandari V 2002 Developmental differences in the role of interleukins in hyperoxic lung injury in animal models. Front Biosci 7: d1624–d1633
Bhandari V, Elias JA 2006 Cytokines in tolerance to hyperoxia-induced injury in the developing and adult lung. Free Radic Biol Med 41: 4–18
Ikegami M, Whitsett JA, Martis PC, Weaver TE 2005 Reversibility of lung inflammation caused by SP-B deficiency. Am J Physiol Lung Cell Mol Physiol 289: L962–L970
Miller TL, Zhu Y, Altman AR, Dysart K, Shaffer TH 2007 Sequential alterations of tracheal mechanical properties in the neonatal lamb: effect of mechanical ventilation. Pediatr Pulmonol 42: 141–149
Dunsmore SE, Saarialho-Kere UK, Roby JD, Wilson CL, Matrisian LM, Welgus HG, Parks WC 1998 Matrilysin expression and function in airway epithelium. J Clin Invest 102: 1321–1331
Li Q, Park PW, Wilson CL, Parks WC 2002 Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111: 635–646
Acknowledgements
We thank Barbara E. Gray, B.A., CPM, Administrative Manager, Nemours Research Lung Center, for her contribution to the research effort.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by Discovery Laboratories, Inc. and NIH COBRE grant # 1P20 RR020173 (The Center for Pediatric Research).
Rights and permissions
About this article
Cite this article
Zhu, Y., Miller, T., Chidekel, A. et al. KL4-Surfactant (Lucinactant) Protects Human Airway Epithelium from Hyperoxia. Pediatr Res 64, 154–158 (2008). https://doi.org/10.1203/PDR.0b013e318175dd14
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/PDR.0b013e318175dd14
This article is cited by
-
Low-Loaded Polyethylene Glycol (PEG) Resin for High-Purity Peptide Synthesis and Cell Binding Assays
BioChip Journal (2023)
-
Lucinactant attenuates pulmonary inflammatory response, preserves lung structure, and improves physiologic outcomes in a preterm lamb model of RDS
Pediatric Research (2012)
-
Giving RSV some POP(G)
Science-Business eXchange (2010)
